Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 1777-1789

  LaPlante, Steven R ^a,c   Nar, Herbert ^b   Lemke, Christopher T ^a   Jakalian, Araz ^a   Aubry, Norman ^a   Kawai, Stephen H ^a,d  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c NMX Solutions ^*  (Canada)

^d Dept of Electrical and Computer Engineering   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FALDAPREVIR; LIGAND; NONSTRUCTURAL PROTEIN 3; PEPTIDE; PROTEASOME; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONFORMATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG INDUSTRY; DRUG POTENCY; DRUG STRUCTURE; HEPATITIS C VIRUS; HUMAN; HYDROGEN BOND; MOLECULAR MODEL; PHARMACOPHORE; PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896311741     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401338c     Document Type: Article

References (48)

1. Teague, S. Implications of protein flexibility for drug discovery Nat. Rev. Drug Discovery 2003, 2, 527-541
2. Weikl, T. R.; von Deuster, C. Selected-fit versus induced-fit protein binding: Kinetic differences and mutational analysis Proteins: Struct., Funct., Bioinf. 2009, 75, 104-110
3. Hammes, G. G.; Chang, Y. C.; Oas, T. G. Conformational selection or induced fit: A flux description of reaction mechanism Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 13737-13741
4. Bakan, A.; Bahar, I. The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 14349-14354
5. Lange, O. F.; Lakomek, N. A.; Fares, C.; Schroeder, G. F.; Gunnar, G.; Walter, K. F. A.; Becker, S.; Meiler, J.; Grubmueller, H.; Griesinger, C.; de Groot, B. L. Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution Science 2008, 320, 1471-1475
6. Kern, D.; Zuiderweg, E. R. The role of dynamics in allosteric regulation Curr. Opin. Struct. Biol. 2003, 13, 748-757
7. Mittermaier, A.; Kay, L. E. New tools provide new insights in NMR studies of protein dynamics Science 2006, 312, 224-228
8. Koshland, D. The active site and enzyme action Adv. Enzymol. Relat. Subj. Biochem. 1960, 22, 45-97
9. LaPlante, S. R.; Bonneau, P. R.; Aubry, N.; Cameron, D. R.; Déziel, R.; Grand-Maiître, C.; Plouffe, C.; Tong, L.; Kawai, S. H. Characterization of the human cytomegalovirus protease as an induced-fit serine protease and the implications to the design of mechanism-based inhibitors J. Am. Chem. Soc. 1999, 121, 2974-2986
10. LaPlante, S. R.; Gillard, J. R.; Jakalian, A.; Aubry, N.; Coulombe, R.; Brochu, C.; Tsantrizos, Y. S.; Poirier, M.; Kukolj, G.; Beaulieu, P. L. Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B J. Am. Chem. Soc. 2010, 132, 15204-15212
11. LaPlante, S. R. Exploiting Ligand and Receptor Adaptability in Rational Drug Design Using Dynamics and Structure-based Strategies Top. Curr. Chem. 2007, 272, 259-296
12. LaPlante, S. R.; Aubry, N.; Deziel, R.; Ni, F.; Xu, P. Transferred 13C T1 relaxation at natural isotopic abundance:A practical method for determining site-specific changes in ligand flexibility upon binding to a macromolecule J. Am. Chem. Soc. 2000, 122, 12530-12535
13. Peng, J. W. New probes of ligand flexibility in drug design: transferred (13)C CSA-dipolar cross-correlated relaxation at natural abundance J. Am. Chem. Soc. 2003, 125, 11116-11130
14. 2 relaxation dispersion at natural abundance J. Biomol. NMR 2009, 45 (1-2) 171-183
15. Peng, J. W. Communication breakdown: Protein dynamics and drug design Structure 2009, 17, 319-320
16. Mauldin, R. V.; Carroll, M. J.; Lee, A. L. Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: Modulation of dynamics within a structural state Structure 2009, 17, 386-394
17. Taylor, R. E.; Chen, Y.; Beatty, A.; Myles, D. C.; Zhou, Y. Conformation-activity relationships in polyketide natural products: A new perspective on the rational design of Epothilone analogues J. Am. Chem. Soc. 2003, 125, 26-27
18. X analogues correlates with their affinity to E-selectin Angew. Chem., Int. Ed. 2001, 125, 1941-1945
19. LaPlante, S. R.; Cameron, D. R.; Aubry, N.; Lefebvre, S.; Kukolj, G.; Maurice, R.; Thibeault, D.; Lamarre, D.; Llinàs-Brunet, M. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain J. Biol. Chem. 1999, 274, 18618-18624
20. Llinàs-Brunet, M.; Bailey, M.; Fazal, G.; Goulet, S.; Halmos, T.; LaPlante, S. R.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Thibeault, D.; Wernic, D.; Lamarre, D. Peptide-based inhibitors of the hepatitis C virus serine protease Bioorg. Med. Chem. Lett. 1998, 8, 1713-1718
21. Llinàs-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors Bioorg. Med. Chem. Lett. 2000, 10, 2267-2270
22. LaPlante, S. R.; Aubry, N.; Bonneau, P.; Kukolj, G.; Lamarre, D.; Lefebvre, S.; Li, H.; Llinàs-Brunet, M.; Plouffe, C.; Cameron, D. R. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain Bioorg. Med. Chem. Lett. 2000, 10, 2271-2274
23. Goudreau, N.; Cameron, D. R.; Bonneau, P.; Gorys, V.; Plouffe, C.; Poirier, M.; Lamarre, D.; Llinàs-Brunet, M. NMR structural characterization of peptide inhibitors bound to the hepatitis C virus NS3 protease: Design of a new P2 substituent J. Med. Chem. 2004, 47, 123-132
24. Lemke, C. T.; Goudreau, N.; Zhao, S.; Hucke, O.; Thibeault, D.; Llinàs-Brunet, M.; White, P. W. Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335 J. Biol. Chem. 2011, 286, 11434-11443
25. Kawai, S. H.; LaPlante, S. R.; Llinàs-Brunet, M.; Hucke, O. The effect of the P1 side-chain on the binding of optimized carboxylate and activated carbonyl inhibitors of the hepatitis C virus NS3 protease Fut. Med. Chem. 2010, 2, 1073-1081 and references therein
26. LaPlante, S. R.; Aubry, N.; Bonneau, P. R.; Cameron, D. R.; Lagacé, L.; Massariol, M.-J.; Montpetit, H.; Plouffe, C.; Kawai, S. H.; Fulton, B. D.; Chen, Z.; Ni, F. Biochemistry 1998, 37, 9793-9801
27. Edwards, P. J.; LaPlante, S. R. Peptides as Leads for Drug Discovery, in Peptide Drug Discovery and Development; Castanho, M.; Santos, N. C., Eds.; Wiley: New York, 2011; pp 3-55.
28. Nar, H.; Bauer, M.; Schmid, A.; Stassen, J.-M.; Wienen, W.; Priepke, H. W. M.; Kauffmann, I. K.; Ries, U. J.; Hauel, N. H. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors Structure 2001, 9, 29-37
29. Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D.; Goudreau, N.; Kukolj, G.; LaPlante, S. R.; Llinas-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection Angew. Chem., Int. Ed. 2003, 42, 1356-1360
30. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; St George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C. L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 2003, 426, 186-189
31. LaPlante, S. R.; Llinàs-Brunet, M. Dynamics and structure-based design of drugs targeting the critical serine protease of the hepatitis C virus-from a peptidic substrate to BILN 2061 Curr. Med. Chem.: Anti-Infect. Agents 2005, 4, 111-132
32. Llinàs-Brunet, M.; Bailey, M. D.; Goudreau, N.; Bhardwaj, P. K.; Bordeleau, J.; Bös, M.; Bousquet, Y.; Cordingley, M. G.; Duan, J.; Forgione, P.; Garneau, M.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Kawai, S. H.; Naud, J.; Poupart, M. A.; White, P. W. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335) J. Med. Chem. 2010, 53, 6466-6476
33. Hinrichsen, H.; Benhamou, Y.; Wedemeyer, H.; Reiser, M.; Sentjens, R. E.; Calleja, J. L.; Forns, X.; Erhardt, A.; Cronlein, J.; Chaves, R. L.; Yong, C. L.; Nehmiz, G.; Steinmann, G. G. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients Gastroenterology 2004, 127, 1347-1355
34. Zeuzem, S.; Asselah, S.; Angus, P.; Zarski, J.-P.; Larrey, D.; Mullhaupt, H.; Gane, E.; Schuchmann, M.; Lohse, A.; Pol, S.; Bronowicki, J.-P; Roberts, S.; Arasteth, A.; Zoulim, A.; Heim, M.; Stern, J. O.; Kukolj, G.; Nehmiz, H.; Haefner, C.; Boecher, W. O. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 2011, 141, 2047-2055
35. Zeuzem, S.; Soriano, V.; Asselah, T.; Bronowicki, J.-P.; Lohse, A.; Müllhaupt, B.; Schuchmann, M.; Bourliere, M.; Buti, M.; Roberts, S.; Gane, E.; Stern, J. O.; Kukolj, G.; Dai, L.; Böcher, W. O.; Mensa, F. J. SVR4 and SVR12 with an interferon-free regimen of BI201335 AND BI207127, ± ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 J. Hepatol. 2012, 56 (Suppl. 2) S45
36. Zeuzem, S.; Soriano, V.; Asselah, T.; Bronowicki, J.-P.; Lohse, A. W.; Müllhaupt, B.; Schuchmann, M.; Bourlière, M.; Buti, M.; Roberts, S. K.; Gane, E. J.; Stern, J. O.; Vinisko, R.; Kukolj, G.; Gallivan, J.-P.; Böcher, W.-O.; Mensa, F. J. Faldaprevir and Deleobuvir for HCV Genotype 1 Infection N. Engl. J. Med. 2013, 369, 630-639
37. The peptide/protease subsite nomenclature used is that of Schechter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 27, 157-162 where the amino acid residues are denoted...P4-P3-P2-P1-P1′-P2′..., the scissile bond being situated between P1 and P1′. The notation...S4-S3-S2... etc. is used to indicate the corresponding binding subsites on the enzyme.
38. Bax, A.; Davis, D. G. Practical aspects of two-dimensional transverse NOE spectroscopy J. Magn. Reson. 1985, 63, 207-213
39. Bax, A.; Grzesiek, S. In Encyclopedia of Nuclear Magnetic Resonance; Grant, D. M.; Harris, R. K., Eds; Wiley: New York, 1996; pp 4157-4167.
40. Hwang, T.-L.; Shaka, A. J. Cross relaxation without TOCSY: transverse rotating-frame Overhauser effect spectroscopy J. Am. Chem. Soc. 1992, 114, 3157-3159
41. Hwang, T.-L.; Shaka, A. J. Reliable two-dimensional rotating-frame cross-relaxation measurements in coupled spin systems J. Magn. Reson., Ser. B 1993, 102, 155-165
42. Baleja, J. D.; Moult, J.; Sykes, B. D. J. Magn. Reson. 1990, 87, 375-384
43. Neuhaus, D.; Williamson, M. P. The Nuclear Overhauser Effect in Structural and Conformational Analysis; VCH: New York, NY, 1989.
44. Wüthrich, K. NMR of Proteins and Nucleic Acids; John Wiley & Sons: New York, NY, 1986.
45. Rancourt, J.; Cameron, D. R.; Gorys, V.; Lamarre, D.; Poirier, M.; Thibeault, D.; Llinàs-Brunet, M. Peptide-based inhibitors of the hepatitis C virus NS3 protease: Structure-activity relationship at the C-terminal position J. Med. Chem. 2004, 47, 2511-2522
46. Kawai, S. H.; Bailey, M. D.; Halmos, T.; Forgione, P.; LaPlante, S. R.; Llinas-Brunet, M.; Naud, J.; Goudreau, N. The use of chemical double-mutant cycles in biomolecular recognition studies: Application to HCV NS3 protease inhibitors ChemMedChem 2008, 3, 1654-1657
47. Kawai, S. H.; Aubry, N.; Duceppe, J.-S.; Llinàs-Brunet, M.; LaPlante, S. R. Dimethylthiazolidine carboxylic acid as a rigid P3 unit in inhibitors of serine proteases: Application to two targets Chem. Biol. Drug Des. 2009, 74, 517-522
48. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: Applications, opportunities, and challenges of synthetic macrocycles in drug discovery J. Med. Chem. 2011, 54, 1961-2004